What is Lion TCR?
Lion TCR operates at the intersection of advanced immunology and oncology, specializing in the development of T cell receptor (TCR)-T cell therapies. The company is distinguished by its ownership of the largest patented TCR library globally, which provides a versatile foundation for addressing a diverse range of HLA types. This technical moat allows the firm to develop highly personalized and effective treatments for viral-associated cancers, particularly liver cancer. With a state-of-the-art GMP production facility, Lion TCR maintains rigorous control over its manufacturing processes, ensuring clinical-grade quality and scalability. Their market position is defined by a dual focus on scientific rigor and operational excellence, enabling them to bridge the gap between laboratory discovery and bedside application in the fight against chronic viral infections and associated malignancies.
How much funding has Lion TCR raised?
Lion TCR has raised a total of $20M across 1 funding round:
Other Financing Round
$20M
Other Financing Round (2018): $20M, investors not publicly disclosed
Key Investors in Lion TCR
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Lion TCR?
Looking ahead, the company is poised to leverage its recent capital injection to accelerate its ongoing clinical trial programs and deepen its research collaborations. The strategic roadmap involves optimizing the manufacturing of its TCR-T cell products to meet increasing demand while simultaneously exploring new therapeutic indications for its proprietary platform. By focusing on clinical safety and efficacy, Lion TCR aims to establish its therapies as a standard of care for hepatocellular carcinoma. The firm's trajectory suggests a move toward commercialization readiness, supported by its robust intellectual property portfolio and a clear vision for transforming the treatment paradigm for viral-related cancers through precision immunotherapy.
See full Lion TCR company page
